Compare AIIR & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIIR | MRVI |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United Arab Emirates | United States |
| Employees | N/A | N/A |
| Industry | Tobacco | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | N/A | 2020 |
| Metric | AIIR | MRVI |
|---|---|---|
| Price | $6.07 | $6.22 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.13 |
| AVG Volume (30 Days) | 10.0K | ★ 2.6M |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $185,743,000.00 |
| Revenue This Year | N/A | $12.54 |
| Revenue Next Year | N/A | $7.87 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.29 | $2.03 |
| 52 Week High | $8.15 | $7.44 |
| Indicator | AIIR | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 46.13 | 46.11 |
| Support Level | $5.29 | $5.67 |
| Resistance Level | $6.62 | $6.55 |
| Average True Range (ATR) | 0.67 | 0.32 |
| MACD | 0.03 | -0.13 |
| Stochastic Oscillator | 38.36 | 7.39 |
AIR Global PLC operates in the social inhalation products sector and has operations across multiple international markets. Its portfolio includes businesses and products related to shisha and hookah, including flavored shisha molasses, hookah and shisha e-commerce platforms, and charcoal-free shisha devices. The company also conducts product research and testing in partnership with independent laboratories to support the development of inhalation-related products and technologies.
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.